medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2018, Number 4

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2018; 34 (4)

Infections in children undergoing hematopoietic stem cell transplantation

Jaime FJC, Castellanos HL, Díaz MJC, Sarduy SS, Llerena MD, Roque GW

Language: Spanish
References: 59
Page: 41-57
PDF size: 172.40 Kb.


ABSTRACT

Introduction: Infections represent a frequent and potentially serious complication for recipients of hematopoietic stem cell transplantation (HSCT).
Objective: To describe the infections in the pediatric patients receiving HSCT.
Methods: A descriptive and cross-sectional study was carried out at the Institute of Hematology and Immunology (IHI) between 1986 and 2016. The frequency, distribution and percentages of the selected variables were obtained.
Results: The universe was studied (n = 47), the average age was 11 ± 4 years. The main indications of HSCT were acute leukemias. Infections affected 87.2% of the cases. There were 67 infectious episodes, in 25 (37.3%) the causative agent could not be identified. Gram-positive bacteria were isolated more frequently (29.9%), with a predominance of Staphylococcus coagulase negative and Staphylococcus viridans . Gram negative bacteria, viruses, fungi and protozoa followed in descending order of frequency. Sepsis was the direct cause of death in 6 (35.3%) of the 17 deceased. Mortality from early infection (83.3%) exceeded late mortality and was generally higher in allogeneic HSCT (66.6%) and when the bone marrow was used as a source of cells (66.6%).
Conclusions: Infections are the most common complications in these children; its frequency increases due to different factors that depend on the type of transplant, the time elapsed, and the presence of other complications; they also constitute an important cause of early mortality.


REFERENCES

  1. Thomas ED. History, current results, and research in marrow transplantation. Perspect Biol Med. 1995 Winter;38(2):230-7.

  2. Majhail NS, Rizzo JD, Lee SJ, Aljurf M, Atsuta Y, Bonfim C, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012 Mar;18(3):348-71.

  3. Majhail NS, Farnia SH, Carpenter PA, Champlin RE, Crawford S, Marks DI. et al. Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2015 Nov;21(11):1863-9.

  4. Gratwohl A, Baldomero H, Aljurf M. Hematopoietic stem cell transplantation: a global perspective. JAMA. 2010; 303:1617-24.

  5. Gratwohl A, Brand R, Niederwieser D. Introduction of a quality management system and outcome after hematopoietic stem-cell transplantation. J Clin Oncol. 2011;29(15):1980-6.

  6. Pasquini MC, Voltarelli J, Atkins HL, Hamerschlak N, Zhong X, Ahn K, et al. Transplantation for autoimmune diseases in north and south América: a report of the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant [Internet]. [citado 2018 Feb 17]; 18 (10): [aprox. 10 p.]. Disponible en: http://www.cibmtr.org/referencecenter/slidesreports/summaryslides/pages/index

  7. Socie G, Rizzo JD. Second solid tumors: screening and management guidelines in long-term survivors after allogeneic stem cell transplantation. Semin Hematol. 2012; 49:4-9.

  8. Charts from world marrow donor association annual report, 2009. [Internet]. [citado 2018 Feb 17] Disponible en: http://www.worldmarrow.org/fileadmin/WorkingGroups_Subcommittees/DRWG/Figur es_WMDA_Website.pdf

  9. Pulsipher MA, Skinner R, McDonald GB. National Cancer Institute, National Heart, Lung and Blood Institute/Pediatric Blood and Marrow Transplantation Consortium First International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: The Need for Pediatric-Specific Long-Term Follow-Up Guidelines. Biol Blood Marrow Transplant. 2012;18(3):334-47.

  10. Passweg JR, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P, et al. Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants. Bone Marrow Transplant. 2015;50:476-82.

  11. Savani BN, Griffith ML, Jagasia S, Lee SJ. How I treat late effects in adults after allogeneic stem cell transplantation. Blood. 2011 Mar 17;117(11):3002-9.

  12. Dorticós-Balea E, Jaime-Fagundo JC, Pavón-Morán V, Reboredo-Domínguez M, Hernández-Ramírez P. Actualización en trasplante de células progenitoras hematopoyéticas en pacientes pediátricos en los últimos 15 años. Rev Cubana Hematol Inmunol Hemoter [Internet]. 2011 [citado 2017 Dic 18]; 27(1): Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864- 02892011000100010&lng=es

  13. Wingard JR, Majhail NS, Brazauskas R, Wang Z, Sobocinski KA, Jacobsohn D et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol 2011;29:2230-9.

  14. Bhatia S, Robison LL, Francisco L, Carter A, Liu Y, Grant M et al. Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study. Blood. 2005;105:4215-22.

  15. Goldman JM, Majhail NS, Klein JP, Wang Z, Sobocinski KA, Arora M et al. Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase. J ClinOncol. 2010;28:1888-95.

  16. Martin PJ, Counts Jr GW, Appelbaum FR, Lee SJ, Sanders JE, Deeg HJ et al. Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J ClinOncol. 2010;28:1011-6.

  17. Armenian SH, Sun CL, Kawashima T. Long-term health-related outcomes in survivors of childhood cancer treated with HSCT versus conventional therapy: a report from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS). Blood. 2011;118(5):1413-20.

  18. Sahin U, Toprak SK, Atilla PA, Atilla E, Demirer T. An overview of infectious complications after allogeneic hematopoietic stem cell transplantation. J Infect Chemother. 2016 Aug;22(8):505-14.

  19. Robak K, Zambonelli J, Bilinski J, Basak GW.Diarrhea after allogeneic stem cell transplantation: beyond graft-versus-host disease.Eur J Gastroenterol Hepatol. 2017May;29(5):495-502.

  20. Syrjala KL, Martin PJ, Lee SJ. Delivering care to long-term adult survivors of hematopoietic cell transplantation. J Clin Oncol. 2012; 30:3746-51.

  21. Khera N, Storer B, Flowers ME. Nonmalignant late effects and compromised functional status in survivors of hematopoietic cell transplantation. J Clin Oncol. 2012;30:71-7.

  22. Young JH, Logan BR, Wu J, Wingard JR, Weisdorf DJ, Mudrick C, et al. Infections after Transplantation of Bone Marrow or Peripheral Blood Stem Cells from Unrelated Donors. Biol Blood Marrow Transplant. 2016 Feb;22(2):359-70.

  23. Seo S, Renaud C, Kuypers JM, Chiu CY, Huang ML, Samayoa E, et al. Idiopathic pneumonia syndrome after hematopoietic cell transplantation: evidence of occult infectious etiologies.Blood. 2015 Jun 11;125(24):3789-97.

  24. Ochs L, Shu XO, Miller J. Late infections after allogeneic bone marrow transplantations: comparison of incidence in related and unrelated donor transplant recipients. Blood. 1995; 86:3979-86.

  25. Arai S, Arora M, Wang T, Spellman SR, He W, Couriel DR, et al. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2015 Feb;21(2):266-74.

  26. Sheridan JF, Tutschka PJ, Sedmak DD, Copelan EA. Immunoglobulin G subclass deficiency and pneumococcal infection after allogeneic bone marrow transplantation .Blood 1990; 75:1583-6.

  27. Kulkarni S, Powles R, Treleaven J. Chronic graft versus host disease is associated with long term risk for pneumococcal infections in recipients of bone marrow transplants. Blood. 2000; 95:3683-6.

  28. NMDP, ASBMT. Recommended Timing for Transplant Consultation, 2011. Sitio en Internet [citado 2016 Feb 19]. Disponible en: http://www.marrow.org/HCT-guide

  29. Melnyk BM, Fineout-Overholt E. Making the case for evidence-based practice. In: Melnyk BM, Fineout-Overholt E. Evidence-based practice in nursing & healthcare. A guide to best practice. 2nded. Philadelphia: Lippincot Williams & Wilkins; 2011. p. 3-24.

  30. Majhail NS, Rizzo JD, Lee SJ, Aljurf M, Atsuta Y, Bonfim C, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012 Mar;18(3):348-71.

  31. S BN. How can we improve life expectancy and quality of life in long-term survivors after allogeneic stem cell transplantation? Semin Hematol. 2012; 49:1-3.

  32. Mo XD, Xu LP, Liu DH. Nonmalignant late effects in survivors of partially matched donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013; 19:777-83.

  33. Bresters D, Van Gils IC, Kollen WJ. High burden of late effects after haematopoietic stem cell transplantation in childhood: a single-centre study. Bone Marrow Transplant. 2010; 45:79-85.

  34. Hannon M, Beguin Y, Ehx G, Servais S, Seidel L, Graux C, et al. Immune Recovery after Allogeneic Hematopoietic Stem Cell Transplantation Following Flu-TBI versus TLI-ATG Conditioning. Clin Cancer Res. 2015 Jul;21(14):3131-9.

  35. Greinix HT, Loddenkemper C, Pavletic SZ. Diagnosis and staging of chronic graftversus- host disease in the clinical practice. Biol Blood Marrow Transplant. 2012; 17(2):67-175.

  36. Wolff D, Gerbitz A, Ayuk F. Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. Biol Blood Marrow Transplant. 2012; 16(12):1611-28.

  37. Lucarelli B, Merli P, Bertaina V, LocatelliF. Strategies to accelerate immune recovery after allogeneic hematopoietic stem cell transplantation. Expert Rev Clin Immunol. 2016;12(3):343-58.

  38. Alonso CD, Treadway SB, Hanna DB, Huff CA, Neofytos D, Carroll KC, et al. Epidemiology and outcomes of Clostridium difficile infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2012 Apr; 54(8):1053-63.

  39. Lang P, Feuchtinger T, Teltschik HM, Schwinger W, Schlegel P, Pfeiffer M, et al. Improved immune recovery after transplantation of TCRαβ/CD19-depleted allografts from haploidentical donors in pediatric patients. Bone Marrow Transplant. 2015 Jun; 50 Suppl 2:S6-10.

  40. Chang YJ, Zhao XY, Huang XJ. Immune reconstitution after haploidentical hematopoietic stem cell transplantation.Biol Blood Marrow Transplant. 2014 Apr;20(4):440-9.

  41. Busca A, Cavecchia I, Locatelli F. Blood stream infections after allogeneic stem cell transplantation: a single-center experience with the use of levofloxacin prophylaxis. Transpl Infect Dis. 2012 Feb;14(1):40-8.

  42. Chen YH, Xu LP, Liu DH, Chen H, Zhang XH, Han W, et al. Comparative outcomes between cord blood transplantation and bone marrow or peripheral blood stem cell transplantation from unrelated donors in patients with hematologic malignancies: a single-institute analysis. Chin Med J (Engl). 2013 Jul; 126 (13):2499-503.

  43. Staciuk R, Figueroa C, Casimi L, Hernández C, Viale D, Paganini H. Complicaciones infecciosas en niños receptores de trasplante hematopoyético alogénico en seguimiento ambulatorio. Revista Medicina Infantil [sitio en internet]. Vol. XV N° 1 Marzo 2008 [citado 2016 Mar 10]; Disponible en: http://www.medicinainfantil.org.ar/index.php/2008-volumen-xv/numero-1/89- complicaciones-infecciosas-en-ninos-receptores-de-trasplante-hematopoyeticoalogenico- en-seguimiento-ambulatorio

  44. Moya I, Muñío JE, Carnot J, Rodríguez Y, Chávez R, Rodríguez CR. Complicaciones infecciosas en el período inmediato precoz postrasplante de progenitores hematopoyéticos. Rev Cubana Med 2012; 51(4) : 291-301.

  45. Lana S, Ortellado D, Villalba M, Lanari A. Trasplante de sangre de cordón umbilical de donante no emparentado. Revista de Posgrado de la VI Cátedra de Medicina. 2006; (158):18-21.

  46. Gutman J A, Turtle J, Manley T J, Heimfield S, Bernstein I D, Riddell S R, et al. Single-unit dominance after double-unit umbilical cord blood transplantation coincides with a specific CD8+ T-cell response against the nonengrafted unit. Blood. 2010; 115 (4):757-65.

  47. Clemmons AB, Albrecht B, Gandhi A, Jacobson S, Pantin J. Impact of Fluoroquinolone ProphylaxisonInfectiou Related Outcomes after Hematopoietic Cell Transplantation: A Single-Center Experience. Biol Blood Marrow Transplant.2016 Jan;22(3):474-5.

  48. Ventola CL. The antibiotic resistance crisis: part 1: causes and threats.P T. 2015 Apr;40(4):277-83.

  49. Tacconelli E, Cataldo MA, Dancer SJ, De Angelis G, Falcone M, Frank U, et al. ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. Clin Microbiol Infect. 2014 Jan; 20 Suppl 1:1-55.

  50. Boeckh M, Murphy WJ, Peggs KS. Reprint of: Recent advances in cytomegalovirus: an update on pharmacologic and cellular therapies. Biol Blood Marrow Transplant. 2015 Feb;21(2 Suppl):S19-24.

  51. Boeckh M, Nichols WG, Chemaly RF, Papanicolaou GA, Wingard JR, Xie H, et al. Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial. Ann Intern Med. 2015 Jan 6;162(1):1-10.

  52. Stockmann C, Roberts JK, Knackstedt ED, Spigarelli MG, Sherwin CM. Clinical pharmacokinetics and pharmacodynamics of ganciclovir and valganciclovir in children with cytomegalovirus infection. Expert Opin Drug MetabToxicol. 2015 Feb;11(2):205-19.

  53. Wilhelm K, Chemaly R, Saliba R, Gulbis A, Saunders I, Cool R.J, et al.The impact of The impact of pre-transplant valganciclovir on early cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation. Oncol Pharm Pract. 2014 Aug;20(4):257-62.

  54. Chemaly RF, Ullmann AJ, Stoelben S, Richard MP, Bornhäuser M, Groth C, et al. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med. 2014 May 8;370(19):1781-9.

  55. Winston DJ, Young JA, Pullarkat V, Papanicolaou GA, Vij R, Vance E, et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebocontrolled, dose-ranging study. Blood. 2008 Jun 1;111(11):5403-10.

  56. Marty FM, Ljungman P, Papanicolaou GA, Winston DJ, Chemaly RF, Strasfeld L. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis. 2011 Apr;11(4):284-92.

  57. Blyth E, Clancy L, Simms R, Ma CK, Burgess J, Deo S. Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation. Blood. 2013 May 2;121(18):3745-58.

  58. Zawilinska B, Szostek S1, Kopec J1, Piatkowska-Jakubas B2, Kosz-Vnenchak M. Multiplex real-time PCR to identify a possible reinfection with different strains of human cytomegalovirus in allogeneic hematopoietic stem cell transplant recipients. Acta Biochim Pol. 2016;63(1):161-6.

  59. Khansarinejad B, Soleimanjahi H, MirabSamiee S, Hamidieh AA, Paryan M, Sanahmadi Y. Monitoring human cytomegalovirus infection in pediat




2020     |     www.medigraphic.com